Montelukast Sumar Pharma (Montelukast Sodium)

Montelukast Sodium, the active ingredient in Montelukast Sumar Pharma, is a leukotriene receptor antagonist presented as an oral dosage form for systemic use. It is indicated for maintenance therapy of asthma, relief of allergic rhinitis symptoms, and prevention of exercise‑induced bronchoconstriction in adults and children.

GNH USA supplies Montelukast Sumar Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation to support import and distribution.

Montelukast Sumar Pharma, a leukotriene receptor antagonist, is used to manage conditions driven by cysteinyl leukotriene–mediated inflammation.

Asthma: reduces frequency of bronchospasm and improves overall disease control. Allergic rhinitis: alleviates nasal congestion, sneezing and itchy eyes. Exercise‑induced bronchoconstriction: prevents airway narrowing during physical activity.

Montelukast is generally well tolerated, but several adverse reactions have been reported.

Common Side Effects: - Headache - Abdominal pain - Cough - Dyspepsia - Fatigue - Nausea

Serious or Rare Side Effects: - Angioedema - Stevens‑Johnson syndrome - Eosinophilic granulomatosis with polyangiitis - Hepatic injury - Anaphylaxis - Mood changes, including depression or suicidal thoughts

When prescribing Montelukast, clinicians should consider several precautionary measures to ensure safe use.

Neuropsychiatric monitoring: observe patients for mood changes, depression or suicidal thoughts. Hepatic function: assess liver status in patients with existing hepatic disease. Severe asthma: use as add‑on therapy and continue other controller medications. Concomitant drugs: review for potential interactions, especially CYP3A4 modulators. Hypersensitivity: discontinue if signs of allergic reaction appear. Store at ambient temperature: keep in original packaging, protect from moisture and heat.

Montelukast may interact with other medicines that affect its metabolism or pharmacodynamic profile.

Major Interactions (Avoid): - Rifampin: strong CYP3A4 inducer that may reduce montelukast plasma levels. - Phenobarbital: enzyme inducer leading to decreased efficacy. - Ketoconazole: potent CYP3A4 inhibitor that can increase montelukast exposure.

Moderate Interactions (Monitor Closely): - Fluconazole: moderate CYP3A4 inhibition, may raise drug levels. - Erythromycin: can increase montelukast concentrations. - Warfarin: potential for altered anticoagulant effect, monitor INR. - Theophylline: monitor for additive bronchial effects.